Tourmaline Bio (NASDAQ:TRML - Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.02, Zacks reports.
Tourmaline Bio Stock Down 2.3 %
Shares of NASDAQ:TRML traded down $0.38 during trading on Monday, reaching $15.92. 233,932 shares of the company traded hands, compared to its average volume of 269,856. The firm has a fifty day simple moving average of $15.22 and a 200 day simple moving average of $19.10. Tourmaline Bio has a 1-year low of $11.56 and a 1-year high of $29.79. The firm has a market cap of $408.91 million, a P/E ratio of -5.65 and a beta of 2.14.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on TRML shares. Wedbush raised their price objective on Tourmaline Bio from $42.00 to $43.00 and gave the stock an "outperform" rating in a research note on Friday, March 14th. HC Wainwright reissued a "buy" rating and issued a $50.00 price target on shares of Tourmaline Bio in a research note on Monday. Chardan Capital reaffirmed a "buy" rating and set a $70.00 price objective on shares of Tourmaline Bio in a research note on Monday. Finally, Lifesci Capital assumed coverage on Tourmaline Bio in a report on Monday, February 24th. They set an "outperform" rating and a $58.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $49.33.
View Our Latest Research Report on Tourmaline Bio
About Tourmaline Bio
(
Get Free Report)
Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.
See Also
Before you consider Tourmaline Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tourmaline Bio wasn't on the list.
While Tourmaline Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
